Problem solved - now lets move forward!CURLF 08:33 Curaleaf Holdings says has addressed issues raised in FDA letter Curaleaf Holdings responded yesterday to a letter from the U.S. FDA informing FDA that the company has addressed the issues that were raised in the letter regarding its CBD product marketing. Upon receiving the letter, Curaleaf Hemp, the company's hemp-based CBD product line, immediately began an extensive review of its website and social media platforms to remove all statements that FDA identified as non-compliant. This includes removing the Curaleaf Hemp blog, and the third-party links in it, and removing any statements and social media posts to which FDA had taken exception. Additionally, Curaleaf Hemp advised FDA that a number of the products mentioned in the FDA letter had previously been discontinued. Curaleaf Hemp will continue to work diligently to ensure that information it provides to consumers on its website and social media platforms are fully compliant with FDA requirements. "Our industry needs, wants and appreciates the work the FDA is doing to ensure there is regulation and compliance in the CBD marketplace," said Joseph Lusardi, CEO of Curaleaf. "We care deeply about our customers and making a difference in our industry. Curaleaf is committed to being an ethical and responsible company and working with the FDA to be a leader in our industry, setting the standards and guidelines to best service our customers and the communities we serve." 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup Read more at: https://thefly.com/landingPageNews.php?id=2939425
Read more at:
https://thefly.com/landingPageNews.php?id=2939425